Vaccine makers including Moderna must hit U.S. timing goals for full payments

The United States is tying payments for COVID-19 vaccines to timing milestones for production and approval, according to public documents and a Trump administration official, putting pressure on drugmakers including Moderna Incto meet ambitious targets.In a deal with Moderna announced this week, federal agencies negotiated a sliding scale of payments.The Cambridge, Massachusetts, biotech's $1.5-billion (1.1 billion pounds) deal pays out in full if its vaccine receives regulatory clearance by Jan